title: Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
authors.forename: Giulio
authors.initials: G
authors.lastname: Metro
authors.forename: Isabella
authors.initials: I
authors.lastname: Sperduti
authors.forename: Michelangelo
authors.initials: M
authors.lastname: Russillo
authors.forename: Michele
authors.initials: M
authors.lastname: Milella
authors.forename: Francesco
authors.initials: F
authors.lastname: Cognetti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Fabi
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012189:Retrospective Studies; D015996:Survival Rate; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab